cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00002964
title: A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia

description: The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.
DOI: 10.25934/00005359
title: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas

description: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cisplatin may also make tumor cells more sensitive to radiation therapy. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy and cisplatin together with cetuximab may kill more tumor cells. It is not yet known whether radiation therapy and cisplatin are more effective with or without cetuximab in treating head and neck cancer. PURPOSE: This randomized phase III trial is studying radiation therapy, cisplatin, and cetuximab to see how well they work compared to radiation therapy and cisplatin in treating patients with stage III or stage IV head and neck cancer.
DOI: 10.25934/00005885
title: A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder

description: The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
DOI: 10.25934/00006126
title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

description: Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance With Moderate to Severe COPD.
DOI: 10.25934/pr00007756
title: A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting

description: The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
DOI: 10.25934/pr00009952
title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus

description: The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
DOI: 10.25934/pr00010345
title: A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors

description: The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R/R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.
DOI: 10.25934/00000226
title: A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.

description: Malaria is an important cause of death and serious illness among Mozambican children. Although the risk of malaria can be reduced by drugs and by impregnated bed nets, it would be helpful if children could be protected against malaria by a vaccine. GSK Biologicals is developing in partnership with Malaria Vaccine Initiative at PATH a candidate malaria vaccine RTS,S/AS02 for the routine immunization of infants and children living in malaria endemic areas. The vaccine would offer protection against malaria disease due to the parasite Plasmodium falciparum and also would provide protection against infection with hepatitis B virus. Previous studies have shown the candidate malaria vaccine RTS,S/AS02 to be safe when administered in adults and children aged 1-11 years. However, to assess if this vaccine could provide protection against malaria in children, this study has been undertaken.
DOI: 10.25934/00000860
title: A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus

description: This study is the second administration of GSK1362885 in humans. GSK1362885 is a novel, potent inhibitor of human glycogen phosphorylase (GP) under development for the treatment of type 2 diabetes mellitus (T2DM). This study will investigate the compound's safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with Type 2 Diabetes Mellitus.
DOI: 10.25934/00001036
title: A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

description: The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.
DOI: 10.25934/00004258
title: Olanzapine Versus Haloperidol in the Treatment of Schizophrenia and Other Psychotic Disorders

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00004266
title: Strategies for Switching from Conventional Antipsychotic Drugs to Olanzapine

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006703
title: A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder

description: The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
DOI: 10.25934/pr00010873
title: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

description: The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).
DOI: 10.25934/00000567
title: Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients

description: This study is planned to objectively assess the efficacy and safety of lamotrigine maintenance therapy after symptoms of mood episode had been stabilised by open-label treatment with lamotrigine alone or in combination with other psychotropic medication in patients with bipolar I disorder.
DOI: 10.25934/00001181
title: MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects With Severe Refractory Asthma

description: This is a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab in comparison with placebo in reducing Oral Corticosteroid (OCS) use in subjects with severe refractory asthma. The study consists of four phases, OCS Optimisation Phase (Week -8 to Week 0), and the double-blind treatment period divided into an Induction Phase (Week 0 to Week 4), OCS Reduction Phase (Week 5 upto Week 20) followed by Maintenance Phase (Week 20 to Week 24). During the Optimisation Phase the investigator will adjust the OCS (prednisone/prednisolone) dose according to the Optimisation titration schedule based on a review of Asthma Control Questionnaire (ACQ)-5 score and exacerbation. In the Induction Phase subjects will be randomized 1:1 (approximately 60 per arm) to receive either mepolizumab (100 mg) administered subcutaneously (SC) or placebo every 4 weeks in addition to their existing maintenance asthma therapy with the lowest dose of OCS from Optimisation Phase. The Induction Phase will allow sufficient time for those subjects randomised to the mepolizumab arm to achieve a decrease in the eosinophilic inflammation prior to the reduction in OCS. During the Reduction Phase, subjects will continue receiving 100 mg mepolizumab/placebo every 4 weeks and the OCS dose reduction will be done every 4 weeks using the reduction titration schedule based on a review of eDiary parameters recorded by the subject, the subjects' exacerbation history, and a review of the signs and symptoms of adrenal insufficiency. In the Maintenance Phase subjects will be maintained without any further OCS dose adjustment. Subjects who complete the 24 week double-blind period and meet the eligibility criteria, will be offered the opportunity to participate in an open label extension (OLE) study otherwise they will return for a Follow-up Visit 12 weeks after their last dose of double blind study treatment. At each clinic visit, adverse events, safety labs, spirometery parameters and exacerbations will be assessed. The pharmacokinetic samples will be collected in the beginning of the treatment, prior to last dose, at the end of study (exit visit) and the follow up.
DOI: 10.25934/00003009.0
title: Available IPD datapackage for study 'A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008191
title: A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus

description: The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.
DOI: 10.25934/00004377
title: Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder

description: How duloxetine compares to a medication currently available for the treatment of depression in the treatment of patients with major depressive disorder. The safety of duloxetine and any side effects that might be associated with it.
DOI: 10.25934/00000142
title: Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.

description: Bipolar study of tolerability, clinical response and patient satisfaction
DOI: 10.25934/pr00008365
title: A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury

description: The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
DOI: 10.17632/nkvffj37z4
title: Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases

description: In the manuscript "Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases" published in Journal of Autoimmunity on May 22 2023 (doi: 10.1016/j.jaut.2023.103051). We describe the in vitro generation of dendritic cells genetically modified to render them pro-tolerogenic and able to modulate unwanted immune responses to auto-antigens both in vitro and in vivo. Raw data for each main figure published in the manuscript are available in the relative.csv file. Read the Read_me.rtf file for more details and for the accession numbers of NGS data deposited at GEO.
DOI: 10.17632/t5pft38mk4
title: Size at sexual maturity and maximum size in shrimps, lobsters and crabs

description: The database corresponds to the bibliographic information collected from various authors and it corresponds to the sizes at sexual maturity and the maximum sizes reported for shrimps, lobsters, and crabs.
DOI: 10.17632/k8g638cmxv
title: A study of Single-cell transcriptome atlas of Drosophila gastrula 2.0. Sakaguchi et al.

description: Processed data (including UMI count tables, Seurat objects, and loom files) and the viewer for browsing the datasets on the browser.
Loom files are compatible with viewing in SCope. The instruction on how to use the viewer is included in the viewer folder.
Raw sequence data were deposited in the DDBJ Sequence Read Archive (DRA) under accession numbers DRA009858, DRA011653, and DRA011680. 
Jupyter Notebooks of code for the processing can be found on the GitHub page (https://github.com/TKondolab/flygastrula2).
DOI: 10.5281/zenodo.15309627
title: Homo floresiensis did not manipulate hammer angle when making stone tools - Data and R code

description: Dataset and R code for reproducing figures and statistical results in 'Homo floresiensis did not manipulate hammer angle when making stone tools', by Lin et al.
DOI: 10.5281/zenodo.15309628
title: Homo floresiensis did not manipulate hammer angle when making stone tools - Data and R code

description: Dataset and R code for reproducing figures and statistical results in 'Homo floresiensis did not manipulate hammer angle when making stone tools', by Lin et al.
DOI: 10.17632/7gbxfg7jy5
title: ZF Sentinels 2021

description: Wild zebrafish sentinels: biological monitoring of pollution using behavior and morphology
DOI: 10.17632/c29frc3y6s
title: Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection. Roussel et al

description: Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS specifically differs from other causes of ARDS remains unknown. To address this crucial question, we build 3 cohorts of patients categorize in COVID-19negARDSpos, COVID-19posARDSpos, and COVID-19posARDSneg, and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood follow by machine-learning based analysis. A cell signature associating S100A9/calprotectin-producing CD169pos monocytes, plasmablasts, and Th1 cells is found in COVID-19posARDSpos, unlike COVID-19negARDSpos patients. Moreover, this signature is essentially share with COVID-19posARDSneg patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We also show an increase in CD14posHLA-DRlow and CD14lowCD16pos monocytes correlate to the occurrence of adverse events during ICU stay. Our study demonstrates that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management. Analyses were performed on a cohort 1 of 63 cryopreserved PBMC samples isolated from 42 patients included in ICU (n = 36) or infectious standard ward (n = 6). All patients but one were classified as severe at admission, requiring oxygen at a flow rate higher than 2 liters/min. ARDS was defined in accordance with international guidelines.34 Patients were classified in 3 groups: COVID-19negARDSpos (n = 12, ARDS stages: 1 mild, 4 moderate, 7 severe), COVID-19posARDSpos (n = 13, ARDS stages: 8 moderate, 5 severe), and COVID-19posARDSneg (n = 17, including 11 from ICU and 6 from infectious standard ward). In the COVID-19posARDSneg, no statistical differences were noticed for immune cell abundance or phenotype between ICU and standard ward patients. Within the COVID-19negARDSpos group, ARDS etiologies were bacterial pneumonia (n = 9), anti-synthetase syndrome (n = 1), and unknown (n = 2). For 21 patients, a second blood sample obtained on day 7 after enrollment was studied (n = 7 for COVID-19negARDSpos, n = 8 for COVID-19posARDSpos, and n = 6 for COVID-19posARDSneg). Additionally, a validation cohort (cohort 2) was set up with 16 patients with demographic data detailed in Table S1 and Table S2. Patients were classified in 3 groups: COVID-19negARDSpos (n = 6), COVID-19posARDSpos (n = 5), and COVID-19posARDSneg (n = 3); additionally, COVID-19negARDSneg (n = 2) samples were included. None of our patients received corticosteroids at the time of the study nor immune-modulators. The presence of SARS-CoV-2 in respiratory specimens (nasal and pharyngeal swabs or sputum) was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) methods.
DOI: 10.17632/dbpnxk8xd5
title: ca and mg isotopic ratios for late Cenozoic carbonates

description: Data include the isotope (δ13C, δ18O, δ44/40Ca, δ26Mg) and element (Mg/Ca, Mg/(Mg+Ca), Sr/Ca, Mn/Sr) values from the South China.
DOI: 10.17632/fvk7m34fdr
title: Amphibian field survey data and trait measurements at the choco region (Colombia) for three different vegetation covers.

description: Amphibians were sampled in the Colombian Pacific Forest, within the Afro-American collective territory of the Community Council of the Upper and Middle Dagua River in the Buenaventura Department. Three types of vegetation cover were selected for study: mature forest, secondary forest and abandoned mixed farming areas, spanning an altitudinal range of 300 to 530 m.a.s.l. (for additional details about the study area, refer to the paper by Cortes-Gomez AM, Castro-Herrera F, Nicolas Urbina-Cardona J (2013) Small changes in vegetation structure create great changes in amphibian ensembles in the Colombian Pacific rainforest. Trop Conserv Sci 6:749–769.
DOI: 10.17632/w2dkncgwjh
title: Wayang Orang

description: Wayang Orang
DOI: 10.21233/m2h9-gw59
title: Sud du Lac du Noyer testate amoebae dataset

description: Raw data for the Sud du Lac du Noyer testate amoebae dataset submitted to the Neotoma Paleoecology Database. Data is available through the landing page in JSON format. The landing page referenced by the DOI also contains links to publications and a map-based viewer for the dataset. The Neotoma Paleoecology Database maintains a homepage at https://www.neotomadb.org.
DOI: 10.17632/zgwh9nncfd
title: Social media in higher education data

description: This is a systematic review of 10 years (2013–2022) of publications on the use of social media in higher education contexts to identify trends and patterns. A total of 92 articles were selected from the Web of Science core database after two stages of searching the literature and manual screening. The literature analysis highlighted four interrelated aspects of social media–based instruction: technical features, instructional design, implementation characteristics, and research design. These four aspects, together with the publications’ metadata, were used to formulate the key coding categories used for the systematic review. The results described changing trends in the social media literature in terms of publication and empirical types, platforms and technical features, instructional design, implementation, and research design. The meta-analysis results also indicated a large overall effect of social media (g = 0.643) and six significant moderating factors: discipline, level of usage, platform, participation type, inquiry level, and assessment context. A list of implications for future practice and research regarding social media on education is provided.
DOI: 10.17632/z7y4fcvv4y
title: Data for: Modeling urban growth by coupling localized spatio-temporal association analysis and binary logistic regression

description: This dataset includes three excel sheets containing the original neighborhood aggregation index (NAI) calculated for sampled points for urbanized land cover type, at different neighborhood sizes (3×3, 5×5, 7×7, 9×9, and 11×11) and time windows (T1: 2016, T2: 2015-2016, and T3: 2014-2016).